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ABSTRACT Epstein-Barr virus DNA was analyzed from
specimens of hairy leukoplakia, an oral lesion that occurs in
patients infected with the human immunodeficiency virus. The
simultaneous presence of both type 1 and type 2 Epstein-Barr
virus was demonstrated by Southern blot analysis and poly-
merase chain reaction assay. Restriction fragment length poly-
morphisms in the BamHI WYH region and in clones of the
EcoRI C region suggested the presence of multiple strains of
ype 1 and type 2 viruses. The demonstration of multiple
variably sized BamHI H fragments on Southern blot analysis
and cloning of the EBNA-2 gene coding region also suggested
the presence of multiple viral strains or variants coinfecting
hairy leukoplakia. Recombination of the viral genome in and
around the EBNA-2 gene apparently generated viral variants
that replicated efficiently, one of which appeared to increase in
abundance in a lesion over time. These data indicate that hairy
leukoplakia involves coinfection with multiple strains of repli-
cating Epstein-Barr virus and the endogenous generation of
viral variants, some of which have mutations of the EBNA-2
gene.
Epstein-Barr virus (EBV) is a lymphotrophic human herpes-
virus that also infects and replicates in oropharyngeal epi-
thelial cells of infectious mononucleosis patients (1) and
EBV-seropositive asymptomatic persons (2). EBV infection
of nasopharyngeal epithelial cells in a latent, nonproductive
form is believed to contribute to the pathogenesis of the
epithelial malignancy nasopharyngeal carcinoma (3, 4). Oral
hairy leukoplakia (HLP), a lesion that occurs on the lateral
border of the tongue in human immunodeficiency virus
(HIV)-infected patients, is caused by EBV (5). The detection
in HLP of viral capsid and early antigens, virus particles, and
heterogeneous EBV termini representing linear DNA indi-
cates a productive, replicative EBV infection (5, 6). Conse-
quently, the lesion clinically responds to acyclovir, a specific
inhibitor of the viral DNA polymerase (7). Therefore, HLP
provides a unique opportunity to study the pathogenesis of
productive EBV infection in epithelial cells.
Two different types ofEBV are distinguished by divergent
DNA sequences in several of the EBV nuclear antigen
(EBNA) genes (8). Type 1 EBV contains the EBNA-2A form
and type 2 EBV contains the EBNA-2B form of the EBNA-2
gene (9). The EBNA-2A gene product is more efficient than
that ofEBNA-2B in the transformation ofB lymphocytes and
transactivation of latent membrane protein expression (10).
Similar to the lymphoblastoid cell line strain P3HR1 (11, 12),
naturally occurring transformation-incompetent variants of
EBV with EBNA-2 gene deletions are found in 15% of
healthy adults and in >90% ofHLP specimens (13). HLP also
contains EBV variants that are genomically rearranged,
similar to the WZhetDNA also described in P3HR1 (14). This
rearrangement results in the expression of a viral gene
product that induces viral replication in B lymphocytes (15).
In this study, the EBV present in DNA extracted froim
multiple HLP biopsy specimens from six HIV-infected pa-
tients was analyzed by Southern blot analysis, PCR, and
cosmid cloning with restriction fragment length polymor-
phism analysis. The data demonstrate a spatially and tem-
porally changing population of multiple strains of both types
ofEBV in HLP. Viral genomes recombine within and around
the EBNA-2 coding sequence, generating new variants that
are defective or deleted for the EBNA-2 gene.
MATERIALS AND METHODS
Southern blots were prepared with DNA extracted from
cultured lymphoblastoid cells and HLP tissue (6, 14). Single-
strandedRNA probes labeled with 32p were synthesized from
EBV DNA fragments cloned into pGEM vectors (Promega),
using either SP6 or T7 RNA polymerase (6). The DNA for
probes 2A-H and 2B-H were derived from pM-BamH2
(MABA) and pJ-HKA7 (Jijoye) (16). The 2A-YH probe was
subcloned from the EcoRI A fragment of the W91 strain from
the Tha I site at base pair (bp) 48,474 in BamHI Y to the Aha
III site at bp 50,305 in BamHI H (17). The 2B-YH probe was
subcloned from the D1 fragment ofthe AG876 strain from the
Mlu I site at bp 48,155 to the Aha III site at bp 50,242 (9). The
clones representing Xho I, EcoRI C, and BamHI W, A, W1,
X, and V have been described (3, 9, 17, 18). Total DNA
extracted from HLP specimens was analyzed by PCR for the
presence ofEBNA-2A and EBNA-2B genotypes (19) and the
presence ofEBNA-2 deletion genomes (13). PCR analysis of
the size of the EBNA-2 gene was performed by amplifying
with oligonucleotide primers whose sequences were derived
from regions ofthe EBNA-2 gene that are conserved between
the 2A (B95-8) and 2B (AG876) types: 5'-CTATCTTGCGT-
TACATGGGGGACA-3' (beginning 11 bases from the ATG
codon) and 5'-GCGAGGTCTTTTACTGGGTCC-3' (ending
13 bases from theTAA codon). Amplification was done in the
presence of 7-deaza-dGTP. The HindIII B and EcoRI C
regions of the EBV genome were cloned from HLP DNA
from three patients into the cosmid vectors Lorist B and
MUA-3 (17, 20).
Abbreviations: HLP, hairy leukoplakia; EBV, Epstein-Barr virus;
HIV, human immunodeficiency virus; EBNA, EBV nuclear antigen;
IR, internal repeat.
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RESULTS
Southern Blot Analysis of the EBNA-2 Region. The EBNA-2
coding sequences were identified on Southern blots by using
four probes (2A-H, 2A-YH, 2B-H, and 2B-YH) that distin-
guish EBNA-2A from EBNA-2B and BamHI H from BamHI
Y (Fig. 1). Hybridization of these probes with Southern blots
of BamHI-digested DNA from the prototype EBV-1 strain,
B95-8, and EBV-2 strain, AG876, demonstrated excellent
type specificity for the BamHI H fragment, but because the
2B-YH probe extends into the BamHI Y region beyond the
divergent sequences, it did not distinguish between the
BamHI Y fragments of EBV-1 and EBV-2 (data not shown).
Two identical Southern blots were prepared of DNA ex-
tracted from HLP biopsy specimens and were sequentially
hybridized, first with a type-specific BamHI H probe and
then with the same-type-specific BamHI YH probe.
Patient A. Four HLP biopsies were obtained over an
18-month period from patient A. Hybridization of the 2A-H
probe to a 5.8-kilobase (kb) BamHI H fragment and hybrid-
ization of the 2B-H probe to a 7.0-kb BamHI H fragment
indicate simultaneous infection with both EBV-1 and EBV-2
within a single lesion (Fig. 2, lane 1). In the subsequent time
point, the 2B form was lost from the lesion and did not
reappear in the lesion on the other side of the tongue (lanes
2-4). In addition, the detection of multiple BamHI H frag-
ments, ranging in size from 5.8 to 12 kb, suggests that more
than one strain or variant ofEBV-1 may be present in a lesion
at one time (lane 3).
A 1.9-kb fragment was detected weakly with the 2A-H
probe, somewhat better with the 2A-YH probe, and very
strongly with the 2B-YH probe. This result suggests that the
1.9-kb fragment contains a small amount of sequence present
in the 2A-H probe linked to sequence present in both the
2A-YH and 2B-YH probes, presumably that at the 5' end
which is conserved between EBV-1 and EBV-2 (Fig. 1). This
fragment could not be detected with the 2A-H or 2A-YH
probes in lane 4 (Fig. 2), which contained less DNA than the
other lanes. However, it could still be detected with the
2B-YH probe, which identified this fragment the most effi-
ciently of the four probes.
Patient B. Three HLP specimens were obtained from
patient B over an 8-month period (data not shown). Simul-
taneous infection with EBV-1 and EBV-2 was also detected
in a single HLP specimen from this patient: a single 1.1-kb
fragment was identified with the 2A-H probe, whereas three
BamHI H fragments, 7.5, 10, and 12 kb in size, were detected
with the 2B-H probe. The 1.1-kb fragment did not contain
sequence from BamHI Y and could represent a strain that
contains an extra BamHI site in the BamHI H portion of the
EBNA-2 gene, similar to the MABA strain from which the
2A-H probe was cloned (16). The absence of a corresponding
BamHI Y fragment may indicate a deletion of its sequence

















FIG. 1. EBNA-2 coding region. W, Y, and H represent BamHI
fragments; A and B represent HindIII fragments. IR, internal repeat.
Arrow represents the open reading frame, and the regions of greatest
divergence between EBV-1 and EBV-2 are shown by the vertical
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FIG. 2. Hybridizations of the four EBNA-2 probes to BamHI-
digested HLP DNA from patient A. Biopsies were taken from two
lesions on opposite sides of the tongue. Lanes 1, early 1987, left side;
lanes 2, 5/20/87, left side; lanes 3, 4/22/88, right side; lanes 4,
8/10/88, right side. Positions of size markers (kb) are at left of each
autoradiogram.
A 7.2-kb fragment in another specimen was identified
strongly by the 2B-YH and BamHI W probes, weakly by the
2A-H and 2A-YH probes, and not at all by the 2B-H probe.
This 7.2-kb fragment contains a small amount of 2A-type
sequence from the BamHI H region connected to sequence
from the BamHI Y region. In another specimen, a 2.7-kb
fragment and a 1.8-kb fragment were identified by the 2B-YH
probe and presumably are 2B-type BamHI Y fragments. The
absence of the corresponding BamHI H fragments suggests
that the EBNA-2 coding sequences are partially deleted in
these two variants.
Patient C. Five HLP specimens from a single contiguous
lesion in patient C obtained over a 1-year period were
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FIG. 3. Hybridizations of the four EBNA-2 probes to BamHI-
digested HLP DNA from patient C. All biopsies were taken from a
single contiguous lesion on the left side of the tongue. Lanes 1,
1/30/90; lanes 2, 6/27/90; lanes 3, 8/16/90; lanes 4, 10/25/90; lanes
5, 12/27/90, longer and shorter autoradiographic exposure times
demonstrating the 1.8-kb and 2.0-kb bands.
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senting EBV-2 were not detected. However, unique popu-
lations of multiple BamHI H fragments, ranging between 4.6
and 8.5 kb, were detected by the 2A-H probe at each time
point, representing either different EBV strains or variants.
The 7.4-kb and 8.5-kb firanents also hybridized to the
BamHI W probe (data not shown), suggesting that these two
fragments represent fusedBamHI Y andH fragments, similar
to the D1 fragment of the AG876 strain (21).
A 1.8-kb fragment was identified by the 2A-H probe at all
the time points. This fragment was not identified by the
2B-YH orBamHIW probes (data not shown) and most likely
represents a truncation ofthe BamHI H fragment, perhaps by
the presence of an additional BamHI restriction site. Several
other small fragments (Fig. 3, lane 1, 0.9 kb; lane 2, 1.2 kb;
lane 3, 0.8 kb; lane 5, 0.8 kb) were identified by the 2A-H
probe but not by the 2B-YH or BamHI W probes (data not
shown) and thus do not contain BamHI Y sequence. They
may represent variants that resulted from deletions of the
EBNA-2 coding sequences in the strain represented by the
1.8-kb BamHI H fragment.
A 1.0-kb fragment (Fig. 3, lanes 3-5), detected by the 2A-H
probe, also hybridized to aBamHI W probe (data not shown)
and the 2B-YH probe but not to the 2B-H probe. This result
indicates the presence of IR 1 sequence (Fig. 1) plus unique
sequence from the 5' end of the 2B-YH probe, as well as
sequence from BamHI H, suggesting a deletion from the
EBNA-2 coding sequence including the BamHI Y/H restric-
tion site. Equal amounts of DNA were loaded on the gel for
each time point (data not shown). The 1.0-kb fragment
became more abundant at the later time point, suggesting that
this deletion variant may replicate more efficiently. Its ab-
sence of hybridization in lane 4 of the 2B-YH blot, which
clearly contained an equal amount ofDNA as demonstrated
by the 2.0-kb fragment, is difficult to explain but perhaps
reflects a loss of sequence contained in the 2B-YH probe at
this time point. Hybridization with the 2A-YH probe identi-
fied a 2.0-kb fragment (lanes 3-5) not detected by the 2A-H
probe. It was also identified by the 2B-YH probe and the
BamHI W probe (data not shown), indicating that this
fragment represents a typical BamHI Y fragment.
These data suggest the presence in patient C of multiple
strains of EBV-1 that are distinguished by restriction frag-
ment length polymorphisms that include (i) the loss of the
restriction enzyme site between BamHI Y and H in the 7.4-
and 8.5-kb fragments, (ii) the addition of a BamHI site
generating the 1.8-kb fragment, and (iii) the presence of the
typical-size BamHI Y andBamHIH fragments. Additionally,
variants of these different strains appear to be generated by
recombination and deletion of sequence in the EBNA-2
region, as demonstrated by the abundant 1.0-kb fragment and
other small fragments, and possibly by recombination in the
IR 2 region as demonstrated by the variably sized 4.6- to
8.5-kb BamHI H fragments.
Patient D. Biopsies of HLP lesions were taken from
opposite sides of the tongue on the same day from patient D.
Hybridization of BamHI-digested DNA with the probe
2B-YH showed two distinct BamHI H-fragment patterns in
the two samples, suggesting that different EBV-2 strains or
variants were replicating simultaneously in separate HLP
lesions (data not shown). Hybridization of the same DNA
with the Xho I probe identified the terminal restriction
fiagment containing the EBV terminal repeat sequences (3).
Unique patterns of terminal fragments in each lesion suggest
that different viral strains were replicating in the two lesions
(data not shown).
Although the analysis of patient D demonstrates that
replicating viral populations may differ between different
lesions on the tongue, the sequential biopsies of a single
contiguous lesion, as performed on patient C, should reflect
the evolution of the viral population of that lesion over time.
Thus, the above hybridization studies indicate that HLP
lesions can have simultaneous infection with EBV-1- and
EBV-2-type virus and may have coinfection with multiple
strains of either type. Variants with different-size BamHI H
fragments or deletions of the EBNA-2 coding sequence may
also arise over time from recombination and rearrangement
during replication within the lesion.
PCR Analysis of the EBNA-2 Region. Total HLP DNA
purified from patients A, B, C, and E was analyzed for the
presence or absence of the 2A and 2B forms of the EBNA-2
gene by PCR (19). Primers derived from conserved regions of
BamHI H amplified a 49-bp variable region that was identi-
fied by oligonucleotide probes specific for EBNA-2A or -2B.
These PCR results generally correlated well with the South-
ern blot analyses and confirmed the findings of coinfection of
HLP with EBV-1 and EBV-2 (Table 1).
HLP DNA from the same four patients was also analyzed
for the presence or absence of EBV variants lacking the
entire EBNA-2 gene, similar to the strains P3HR1 and Daudi,
by PCR as described (13). Primers and nested oligonucleotide
probes flanking the deleted sequence amplified and identified
these variants. DNA from all time points of three of the four
patients demonstrated the presence of viral variants possess-
ing this specific type of EBNA-2 deletion (Table 1). Patient
C did not harbor virus with this particular deletion; however,
Table 1. PCR analysis of EBNA-2 in HLP DNA
EBNA-2 type EBNA-2 EBNA-2 fragment
Patient Date 2A 2B deleted type (size, kb)
A Early 87 + + + ND
5/20/87 ND ND ND ND
4/22/88 - - + 2A (1.1, 1.5)
8/10/88 - - + 2A (0.65, 1.5)
B 4/13/88 - + + -
7/24/88 + + + 2A (1.5) and
2B (0.75, 1.0, 1.3)
12/22/88 + + + 2A (0.6, 1.5)
C 1/30/90 + - - -
6/27/90 + - - -
8/16/90 + - - 2A (0.7, 1.1, 1.5)
10/25/90 + - - 2A (0.7, 1.1, 1.5)
12/27/90 - - - 2A (0.7, 1.1, 1.5)
E 12/30/87 + + + 2A (0.5, 0.8, 1.0, 1.5)
2/2/88 + + + 2A (1.5)
+, Detected; -, not detected; ND, not done.
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small deletions or deletions that involved the primer or probe
sequence used in this assay would not be detectable.
To identify partially deleted and/or rearranged EBNA-2
coding sequences detected by the Southern blot analyses,
conserved-sequence primers were chosen that frame a
1446-bp region within the EBNA-2 coding sequence. As
identified by the four EBNA-2 probes, HLP DNA from all
four patients contained multiple variably sized EBNA-2
coding sequences that were amplified by these primers (Table
1). In one sample of patient B, both EBNA-2A- and EBNA-
2B-type amplified fragments could be differentially identified
(data not shown). Deletions or rearrangements involving the
extreme 5' or 3' ends of the gene would not be detected by
this assay. As demonstrated by the Southern blots, these
PCR results confirm that some EBV variants in HLP contain
deletions from within the EBNA-2 coding sequence.
Cloning of the EBNA-2 Region. HLP DNA from patient A,
4/22/88 (Fig. 2, lane 3), was cloned into the cosmid vector
Lorist B at a HindIII restriction site. The purified cosmid
DNA of nine clones containing EBNA-2 sequence was di-
gested with HindIII and BamHI, electrophoresed, Southern
blotted, and hybridized with the four EBNA-2 probes (data
not shown). Four distinct BamHI H fragments similar in size
to those detected by Southern blot hybridization were con-
tained within clones, indicating the simultaneous in vivo
presence in HLP of these distinct fragments of EBV. Four
clones, including two different BamHI H fragments, were
further analyzed with Bgl II restriction enzyme digestion. In
all four cases, the Bgl II fragment containing the BamHI H
region with the IR 2 elements was the only Bgi II fragment in
the HindIll B region that varied in size between clones (data
not shown).
Two other clones contained small HindIII fragments, 2.5
and 1.4 kb, that hybridized only to the 2A-YH probe and were
not cut by BamHI, indicating that they contained EBNA-2
sequence from the BamHI Y region only (data not shown).
They must represent either strains that contain additional
HindIII sites in the HindIII B region or variants with partially
deleted and rearranged EBNA-2 genes that have lost the
EBNA-2 coding sequence contained in the 2A-H probe. The
latter possibility is compatible with the data from the South-
ern blot and PCR analyses that demonstrated deletions in the
EBNA-2 gene region.
Cloning of the EcoRI C Region. HLP DNA from patients E
and F was cloned into the cosmid vector MUA-3 at an EcoRI
restriction site. The EcoRI C region contains several BamHI
restriction fragment length polymorphisms that distinguish
different strains of EBV (Fig. 4) (17, 21). Purified cosmid
DNA containing EcoRI C was digested with EcoRI and
BamHI restriction enzymes and electrophoresed in an aga-
rose gel (Fig. 5). Southern blotting and sequential hybridiza-
tion identified the BamHI I, A, W1, andX fragments (data not
shown). Each clone from both patients contained a unique
BamHI B1 fragment that spans the IR 4 sequence. One clone
from each patient contained the standard-size BamHI frag-
ments (Fig. 5, lanes 2 and 8), and another clone from each
patient shared a small 1.6-kb BamHI W1 fragment (lanes 4
and 10). A large, 8-kb BamHI I fragment identified another
clone (lane 6), while the last clone was marked by multiple
polymorphisms that included large BamHI A and V frag-
ments, a 4-kb BamHI X fragment, and a 2.1-kb BamHI W1
fragment (lane 12). Restriction fragment length polymor-
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FIG. 4. The EcoRI C fragment. Below the line, E represents an
EcoRI site and B represents a BamHI site. X, V, d, B1, W1, I, and














FIG. 5. Ethidium bromide-stained agarose gel containing EcoRI-
and BamHI-digested EcoRl C cosmid clones from patient E and
patient F. The first lane of each pair is a clone digested with EcoRI,
and the second lane is the same clone digested with EcoRI and
BamHI. The BamHI fragments are labeled for the clone in lane 2,
where they are the standard sizes. The unlabeled band is the cosmid
vector. Lanes 1 and 2, patient E, clone A; lanes 3 and 4, patient E,
clone B; lanes 5 and 6, patient E, clone C; lanes 7 and 8, patient F,
clone A; lanes 9 and 10, patient F, clone B; lanes 11 and 12, patient
F, clone C.
phisms that do not span IR sequence represent distinct strains
of EBV. Three EcoRI C polymorphisms cloned from the
same HLP specimen suggest the presence of three different
coinfecting strains in each patient.
DISCUSSION
Analogous to herpes simplex virus, EBV may be differenti-
ated into two major types, EBV-1 and EBV-2. Within each
type, multiple distinct strains may circulate within a com-
munity and may predominate in specific geographic regions.
Like herpes simplex virus, the EBV strains can be distin-
guished by restriction fragment length polymorphisms, re-
flecting sequence variation at the restriction enzyme site (8,
16, 21). In addition to strain variation, recombination during
replication may generate variants of a single strain that have
genomic rearrangements or that differ in the number of IR
elements, resulting in variably sized restriction fragments
that span these regions.
Coinfection with multiple types and strains ofEBV appar-
ently occurs only rarely in patients with infectious mononu-
cleosis and healthy EBV-seropositive persons (22-25) but
may be more common in immunocompromised patients,
including those with HIV infection (13, 19, 24, 26, 27). The
data presented here show that both EBV-1 and EBV-2 can be
present within a single HLP lesion. The EBV in HLP
contains fragments with normal and deleted EBNA-2 coding
regions, and other variable fragments frequently span the IR
2 or IR 4 regions. These heterogeneous fragments could
represent multiple exogenous infection events with different
wild-type strains or viral variants generated within the lesion
itself by recombination and rearrangement during viral rep-
lication. The data support the existence of both processes
simultaneously in HLP.
The following evidence supports the hypothesis of re-
peated superinfection ofHLP by different strains ofEBV. (i)
Both the EBV-1 and EBV-2 types can coexist in a lesion and
are independently acquired or lost over time. (ii) The restric-
tion fragment length polymorphisms within the EBNA-2 gene
region of patient C suggest simultaneous infection with
multiple strains of type 1 EBV. (iii) Most of the restriction
fragment length polymorphisms in the EcoRI C region do not
involve variable IR sequence but are presumably stable
genotypes representing distinct strains. (iv) Two ofthe EcoRI
C clones obtained from HLP lesions from two different
patients contained an identical small BamHI W1 fragment,
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suggesting that this polymorphism represents a strain that
was acquired independently by both patients.
In addition, the following data suggest that recombinant
and rearranged variant virus is endogenously generated in
HLP. (a) Like the EBNA-2 deleted progeny generated during
productive replication of the B95-8 strain (13), EBNA-2
deleted variants apparently arise within the HLP lesion as a
by-product of productive replication. (b) The numerous de-
leted and rearranged fragments in the BamHI YH region and
the partially deleted EBNA-2 genes detected by PCR vary
greatly between different patients with HLP, suggesting that
these defective fragments do not represent independent
strains circulating in the community. (c) The constancy ofthe
Bgl II restriction fragment pattern in the cloned HindIII B
fragments with different-size BamHI H fragments suggests
that recombination occurs more frequently in the IR 2 region
than in other nearby regions of the genome. This genetic
constancy may indicate a common parentage for the viral
variants, which presumably are generated endogenously and
differ only in the number ofrepeat elements in the IR 2 region.
Alternatively, some of the multiple BamHI H fragments
may represent independently acquired strains. Epidemio-
logic studies have used variably sized BamHI H fragments to
trace EBV infections, because BamHI H-fragment size is
believed to remain constant between sequentially infected
patients (24, 25, 27). The several distinctBamHI H fragments
in the 4.6- to 12-kb range could represent distinct, genetically
stable strains. The sequential acquisition and loss of different
BamHI H fragments may indicate repeated superinfection by
strains originating from the community. Thus, these data
alone cannot conclusively resolve whether the 4.6- to 12-kb
BamHI H fragments represent independently acquired
strains of EBV or variants arising de novo during persistent
replicative infection. This distinction has implications for the
validity of identifying EBV strains by polymorphisms of
restriction fragments that contain variable IR sequence.
In HLP, the numerous EBNA-2-defective variants ofEBV
suggest a biological significance beyond their mere presence
in the lesion. They are replicating with high efficiency and
persisting over long periods of time, and in some samples
they are the most abundant genotype present. The role of
EBNA-2 in epithelial cells is unknown. Despite its impor-
tance in latent B-cell infection, EBNA-2 is not expressed in
latently infected nasopharyngeal carcinoma cells (28), and its
expression in HLP tissue has not been convincingly demon-
strated (29).
Since the expression of EBNA-2 is not necessary for viral
replication, it is unclear how mutating the gene would have
a selective advantage over simply down-regulating its ex-
pression. The deletions in the EBNA-2 gene may be markers
ofother genomic rearrangements and defective DNA, similar
to the WZhet DNA (14) that acts to shift infection from latent
to productive replication in lymphoid cells (15). The subse-
quent high level of viral production may then result in
superinfection and activation of replication in contiguous,
latently infected epithelial cells (30). Exogenous EBV strains
may enter the oropharynx and replicate as well. However,
the loss of particular strains over time suggests that the
infection is superficial, a hypothesis supported by the in situ
hybridization findings of latent membrane protein expression
without expression of the EBV-encoded small nuclear RNAs
in the basal layer of HLP (6).
In summary, HLP is a lytic, replicative form of epithelial
infection with EBV. The data from HLP biopsy specimens
demonstrate a previously undescribed degree of spatial and
temporal heterogeneity and genomic complexity of the in-
fecting EBV population. Coinfection with multiple exoge-
nous types and strains ofEBV occurs in HLP, and additional
viral variants are generated endogenously during productive
replication. Many of the variants contain alterations in and
around the EBNA-2 coding region. These defective viruses
may play a role in the biology and pathogenesis of this
infection of immunocompromised patients.
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